News and events

  • All
  • Events
  • Press releases
  • Publications
All
  • All
  • Events
  • Press releases
  • Publications

ExeVir announces first subjects dosed Phase 1 clinical study of potent COVID-19 neutralizing antibody

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a ...
Read More

ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, and Mithra Pharmaceuticals (Euronext Brussels: MITRA) announce a new collaboration to ...
Read More

ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has generated data on its COVID-19 antibody ...
Read More

ExeVir Announces Close of $50 million/ EUR42 million Series A Financing

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising ...
Read More

ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection against SARS-COV-2 and related coronaviruses

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, announces publication in BioRxiv of a paper by VIB scientists showing, ...
Read More